See: "Drugs in 2019: a brief review" Prescrire Int 2020; 29 (214): 110-111. (Pdf, free).
 

See: "Drugs in 2019: a brief review" Prescrire Int 2020; 29 (214): 110-111. (Pdf, free).

• emicizumab in patients with haemophilia A and factor VIII inhibitors (Prescrire Int n° 210).

• chenodeoxycholic acid in cerebrotendinous xanthomatosis (Prescrire Int n° 207);
  glecaprevir + pibrentasvir for adolescents with chronic hepatitis C (Rev Prescrire n° 434);
• axicabtagene ciloleucel in certain types of lymphoma when other treatment options have been exhausted (Prescrire Int n° 208);
• durvalumab as "maintenance" treatment in lung cancer (Prescrire Int n° 212);
• pembrolizumab in combination with cytotoxic drugs in lung cancers when a small proportion of tumour cells express the PD-L1 protein (Prescrire Int n° 212);
• raltegravir granules for neonates with HIV infection (Rev Prescrire n° 431);
• ruxolitinib in myelofibrosis (Prescrire Int n° 205);
• tisagenlecleucel for children and young adults with certain types of acute lymphoblastic leukaemia (Prescrire Int n° 208);
• trastuzumab emtansine in inoperable breast cancer (Prescrire Int n° 207);
• trientine in Wilson's disease (Prescrire Int n° 214)

• emtricitabine + tenofovir disoproxil for prevention of HIV infection in adolescents (Prescrire Int n° 206);
• atazanavir oral powder for patients from 3 months of age with HIV infection (Prescrire Int n° 207);
• baclofen in alcohol dependence (Prescrire Int n° 212);
• cenegermin eye drops in neurotrophic keratitis (Prescrire Int n° 204);
• colchicine in acute pericarditis (Prescrire Int n° 211);
• dupilumab in adults with atopic eczema (Prescrire Int n° 204);
• erenumab for prevention of migraine attacks (Prescrire Int n° 207);
• glycopyrronium for sialorrhoea due to neurological disorders (Rev Prescrire n° 430);
• metreleptin in lipodystrophy with leptin deficiency (Rev Prescrire n° 434);
• pasireotide for intramuscular use in Cushing's disease (Rev Prescrire n° 425);
• peginterferon alfa-2a for patients from 3 years of age with chronic hepatitis B (Rev Prescrire n° 423);
• glycerol phenylbutyrate in urea cycle disorders (Rev Prescrire n° 428);
• tocilizumab for subcutaneous use in giant cell arteritis (Prescrire Int n° 205).
  

• adalimumab in children with chronic anterior uveitis (Rev Prescrire n° 429);
• brentuximab vedotin in cutaneous T-cell lymphoma (Rev Prescrire n° 426);
• burosumab in X-linked hypophosphataemia (Prescrire Int n° 206);
• cerliponase alfa in neuronal ceroid lipofuscinosis type 2 (Prescrire Int n° 213);
• darvadstrocel for complex perianal fistulae in Crohn's disease (Prescrire Int n° 213);
• mogamulizumab in mycosis fungoides and Sézary syndrome (Rev Prescrire n° 434);
• oxycodone + naloxone in restless legs syndrome (Prescrire Int n° 205);
• sirolimus in sporadic lymphangioleiomyomatosis (Prescrire Int n° 212);
• tocilizumab in cytokine release syndrome due to CAR T-cell therapy (Rev Prescrire n° 428).

• abemaciclib in certain types of breast cancer (Rev Prescrire n° 431);
• colchicine + opium + tiemonium in acute pericarditis (Prescrire Int n° 211);
• ataluren for children aged 2 to 4 years with Duchenne muscular dystrophy (Prescrire Int n° 213);
• chondroitin 1200 mg oral gel in sachets (Rev Prescrire n° 424);
• ertugliflozin in type 2 diabetes (Prescrire Int n° 213);
• ethinylestradiol + dienogest for contraception or acne (Rev Prescrire n° 426);
• recombinant human parathyroid hormone in chronic hypoparathyroidism (Prescrire Int n° 210);
• mepolizumab for patients from 6 years of age with severe asthma (Prescrire Int n° 211);
• olaparib in ovarian cancer without a BRCA mutation (Prescrire Int n° 209);
• pentosan polysulfate in bladder pain syndrome (Prescrire Int n° 204);
• pertuzumab as adjuvant treatment for certain types of breast cancer at high risk of recurrence (Prescrire Int n° 210);
• solifenacin oral solution in neurogenic detrusor overactivity in children (Rev Prescrire n° 429);
• tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat for children with HIV infection (Prescrire Int n° 206);
• tolvaptan in polycystic kidney disease with severe renal failure (Rev Prescrire n° 431).